|CIPA Congress can be fun -- but there's|
a thoroughly serious side to it
"A full and diverse panel has now been confirmed for Session 7, which addresses a range of important issues facing actors in the world of licensing and commercialisation. Experienced in-house attorney Greg Corcoran of ASML chairs the session and will coordinate talks from three very different perspectives.If you can get there, Congress takes place on 2 and 3 October at the Lancaster London Hotel, London W2 2TY. For further information and registration details, click here.
* Dr Kevin Scott (Royal Philips) will share his experience and expertise from the perspective of a large, innovative multinational, discussing various ways that licensing and open innovation models can be used to achieve effective collaborations and extract value from innovations. He will provide insight on how a multinational can leverage its IP to obtain the best return on investment.
* Dr Hayley French will provide views from a dynamic young biotechnology firm, Apitope International, which has used licensing agreements to forge partnerships with investors and pharmaceutical companies worldwide. She will discuss the techniques employed by a young biotech firm to use its IP to survive in a highly competitive market.
* Dr Adam Stoten will share experience gained over 25 years by Isis Innovation, one of the UK's leading university tech transfer organisations. Having executed more than 1,000 commercial licences and supported the creation of more than 80 new companies, Isis has had the opportunity to see over the long term how agreements really stand the test of time. He will share ideas about how an established tech transfer organisation translates academic discoveries into real products and services which benefit society."
I'm and admirer of Isis Innovation and the way they share their expertise with other tech transfer organisations. However I want to introduce a note of caution. Research done at Oxford University tends to be of higher quality and ground breaking. That makes it easier to get broad patent claims. Research done at many other institutions will not be like that, and so won't lead to broad patents, and won't be as easy to commercialise. Therefore replicating Isis Innovation's success is not as easy as it sounds.
Post a Comment